We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




New One-Stage Factor VIII Assay Evaluated

By LabMedica International staff writers
Posted on 17 Mar 2022
Print article
Image: The cobas t 711 coagulation analyzer (Photo courtesy of Roche Diagnostics)
Image: The cobas t 711 coagulation analyzer (Photo courtesy of Roche Diagnostics)

Factor VIII (FVIII) is a multi-domain glycoprotein that is synthesized in the liver. As an essential blood coagulation protein required for normal hemostasis, FVIII circulates in plasma at normal concentrations of around 50–150 international units (IU)/dL in a non-covalent complex with von Willebrand factor.

FVIII is activated to factor VIIIa via limited proteolysis by thrombin and then acts as a cofactor to activated factor IX, during the activation of factor X to factor Xa, ultimately leading to clot formation. Deficiency of or dysfunctional FVIII leads to a bleeding diathesis of varying severity, depending on FVIII levels and/or activity.

Hematologists at the Sheffield Haemophilia and Thrombosis Centre (Sheffield, UK) and their international colleagues conducted a multicenter evaluation of a new one-stage factor VIII (FVIII) assay (Roche Diagnostics, Rotkreuz, Switzerland), intended for the quantitative assessment of FVIII activity. The team evaluated the analytical performance of the FVIII assay on a Roche analyzer.

Anonymized human 3.2% citrated plasma samples, both fresh and frozen to reflect routine laboratory practice, were used throughout the study. FVIII activity was assessed using the new one-stage FVIII assay on the cobas t 711 analyzer. Five human plasma pools and two controls were used to determine assay within-run and within-laboratory precision, and total reproducibility; coefficients of variation (CVs) and/or standard deviations (SDs) were calculated. Lot-to-lot variability and method comparison versus Coagulation FVIII Deficient Plasma/Dade Actin FS Activated PTT reagent/Standard Human Plasma Calibrator on the Sysmex CS-5100 analyzer (Milton Keynes, UK) and were evaluated by Passing–Bablok and Deming regression, respectively, and Pearson's r calculated. Assay-specific reference range was determined using 199 fresh plasma samples from healthy adults, not receiving anticoagulants.

The investigators reported that the method comparisons were conducted at three international sites across the primary measuring range of both the new one-stage FVIII assay on the cobas t 711 analyzer and reference comparator assay on the Sysmex CS-5100 analyzer. Good agreement between the new one-stage FVIII assay and comparator assay was observed at three different sites. Among apparently healthy individuals, FVIII activity ranged from 82.2 to 218.0 IU/dL in fresh samples and from 79.8 to 211.0 IU/dL in frozen samples.

The authors concluded that the new one-stage FVIII assay demonstrated robust analytical performance on the cobas t 711 analyzer, supporting its use in routine laboratory practice. The study was published on March 11, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
Sheffield Haemophilia and Thrombosis Centre 
Roche Diagnostics 
Sysmex 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Auto Clinical Chemistry Analyzer
cobas c 703

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.